Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease
Authors:
Open Access
- 30 June 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (7) , 1176-1183
Abstract
Background. Currently, there are few strategies for improving the quality of life (QOL) in patients with autosomal dominant polycystic kidney disease (ADPKD) and massive kidneys. Renal transcatheter arterial embolization (TAE) reduces kidney volume, but its impact on QOL in ADPKD patients on hemodialysis is unknown. This study investigated the influence of renal TAE on QOL in ADPKD patients with massive kidneys receiving hemodialysis. Methods. This prospective observational study enrolled 188 ADPKD patients on hemodialysis (92 men and 96 women; mean age 56.7 ± 9.1 years) who underwent renal TAE at Toranomon Hospital between August 2010 and July 2014. The 36-item Short Form Health Survey (SF-36) and our original 15-item questionnaire were used to evaluate QOL. Results. Using a linear mixed model, the least squares mean values of the SF-36 physical component summary (PCS), mental component summary (MCS) and role/social component summary (RCS) before renal TAE were calculated as 38.21 [95% confidence interval (CI) 36.50–39.91], 48.45 (47.05–49.86) and 43.04 (40.70–45.37), respectively. These values improved to 42.0 (40.22–43.77; P < 0.001 versus before TAE), 51.25 (49.78–52.71; P = 0.001) and 49.67 (47.22–52.12; P < 0.001), respectively, 1 year after renal TAE. Scores for abdominal fullness, poor appetite and heartburn showed marked improvement after renal TAE, while scores for fever, bodily pain and sleep disorder also improved slightly, but significantly. Scores for constipation and use of analgesics/sleeping medications/laxatives did not improve significantly. All of the SF-36 scores and the scores for specific symptoms (except bodily pain, snoring and constipation) were significantly correlated with the sequential decrease of the height-adjusted total kidney volume. Conclusions. In ADPKD patients on hemodialysis, renal TAE was effective in improving abdominal fullness, appetite, heartburn and SF-36 scores (MCS and RCS scores), but not for sleep disturbance, constipation and physical strength (PCS score).Keywords
This publication has 26 references indexed in Scilit:
- Embolization of renal arteries before transplantation in patients with polycystic kidney disease: a single institution long-term experienceEuropean Radiology, 2015
- Renal artery embolization—indications, technical approaches and outcomesNature Reviews Nephrology, 2014
- Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney diseaseKidney International, 2014
- Survival after arterial embolization therapy in patients with polycystic kidney and liver diseaseJournal Of Nephrology, 2014
- Health-Related Quality of Life in Patients With Autosomal Dominant Polycystic Kidney Disease and CKD Stages 1-4: A Cross-sectional StudyAmerican Journal of Kidney Diseases, 2014
- Bilateral Nephrectomy Significantly Improves Health-Related Quality of Life in a Hemodialysis Patient With Autosomal Dominant Polycystic Kidney DiseaseAmerican Journal of Kidney Diseases, 2013
- Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional studyBMC Nephrology, 2013
- Simultaneous Bilateral Native Nephrectomy and Living Donor Renal Transplantation are Successful for Polycystic Kidney Disease: The University of Maryland ExperienceJournal of Urology, 2009
- Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patientsAmerican Journal of Kidney Diseases, 2002
- Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 1993